Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Rheumatology

Your Scleroderma Subtype and Antibody Profile

At a Glance

In systemic sclerosis (scleroderma), your specific autoantibody profile—like ACA, anti-Scl-70, or anti-RNA polymerase III—is the most reliable predictor of future health risks. While skin changes can fluctuate, antibodies provide a stable blueprint for which internal organs need monitoring.

While every journey with systemic sclerosis (SSc) is unique, doctors use two main “maps” to understand how the disease might behave: your skin subtype and your autoantibody profile. While skin changes are the most visible part of SSc, your antibodies often provide a more stable and accurate “blueprint” for what is happening inside your body [1][2].

The Three Main Clinical Subtypes

Historically, SSc is categorized by how much of your skin is affected. This helps doctors predict the “speed” of the disease and which organs might be involved [1].

  • Limited Cutaneous SSc (lcSSc): Skin thickening is “limited” to the areas below the elbows and knees, and sometimes the face and neck. Raynaud’s phenomenon often exists for years before other symptoms appear [3]. While it often progresses more slowly, there is a long-term risk of high blood pressure in the lungs (pulmonary arterial hypertension) [4].
  • Diffuse Cutaneous SSc (dcSSc): Skin thickening can affect the upper arms, thighs, and trunk. It often develops more rapidly [1]. This subtype is more likely to involve internal organs like the lungs, heart, or kidneys earlier in the disease course [5].
  • Sine Scleroderma (ssSSc): This is a rare variant where there is no visible skin thickening, but the patient has the internal organ involvement and antibodies typical of SSc [6]. Despite the lack of skin symptoms, these patients still require careful monitoring for organ complications [7].

Your Antibody Profile: The Internal Blueprint

Autoantibodies are proteins made by your immune system that mistakenly target your own cells. In SSc, these antibodies are highly specific—most people only have one type, and it almost never changes over time [1][8]. This makes them a “robust predictor” of your specific risks [9].

Antibody Interpretation Guide

The table below shows the most common antibodies and the clinical trajectories they usually predict.

Antibody Most Common Subtype Key Organ Risks & Trajectory
Anti-Centromere (ACA) Limited (lcSSc) Generally a slower progression. Higher risk for pulmonary arterial hypertension (lung blood pressure) later in life [10][4].
Anti-Scl-70 (Anti-Topoisomerase I) Diffuse (dcSSc) Higher risk and greater severity of interstitial lung disease (ILD), or scarring of the lung tissue [1][11].
Anti-RNA Polymerase III Diffuse (dcSSc) Rapid skin changes. Higher risk for scleroderma renal crisis (sudden high blood pressure/kidney issues) and a possible increased risk for malignancy (cancers) [12][13].

Why Antibodies Matter More Than Skin

While your skin score (how thick the skin feels) can fluctuate or even improve over time, your antibody profile stays the same [2]. Recent research suggests that an “antibody-only” model is often better at predicting your future health than looking at skin alone [9].

For example, a person with “limited” skin involvement but the Anti-Scl-70 antibody may actually be at a higher risk for lung scarring than someone with “diffuse” skin but no such antibody [11]. Understanding your “type” allows your medical team to personalize your monitoring—such as frequent lung scans for those with Scl-70 or daily blood pressure checks for those with RNA Polymerase III—to catch and treat complications as early as possible [14][15].

Common questions in this guide

What is the difference between limited and diffuse scleroderma?
Limited scleroderma involves skin thickening mainly on the arms, legs, and face. Diffuse scleroderma spreads more rapidly and affects the upper arms, thighs, and trunk, carrying a higher risk of early internal organ involvement.
Why are autoantibodies important in systemic sclerosis?
Autoantibodies act as a consistent blueprint for how your scleroderma may behave. Because your antibody profile rarely changes, it is a highly accurate tool for predicting which organs are at risk, often more so than skin changes alone.
What does a positive anti-Scl-70 antibody mean?
The anti-Scl-70 antibody is often linked to diffuse cutaneous scleroderma. It indicates a higher risk for developing interstitial lung disease, which is scarring of the lung tissue, requiring close monitoring of your lung function.
What should I watch for if I have the anti-RNA polymerase III antibody?
This antibody is associated with rapid skin changes and a high risk of scleroderma renal crisis. If you have this antibody, you should regularly check your blood pressure at home to catch sudden spikes or kidney issues early.
Can you have systemic sclerosis without skin thickening?
Yes, a rare variant called sine scleroderma occurs when a person has no visible skin thickening but still has the internal organ involvement and specific autoantibodies typical of systemic sclerosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my antibody results, which organ systems (like lungs or kidneys) should we be most concerned about?
  2. 2.How often should I have pulmonary function tests (PFTs) or echocardiograms to monitor for silent organ involvement?
  3. 3.If I have the anti-RNA polymerase III antibody, what symptoms of 'renal crisis' should I watch for besides high blood pressure?
  4. 4.Do I need to be screened more frequently for certain types of cancer based on my antibody profile?
  5. 5.Does my skin subtype (limited vs. diffuse) change the way we use medications, or is it more about the antibodies?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Exploratory clinical subgroup clustering in systemic sclerosis: Results from the Indian Progressive Systemic Sclerosis Registry.

    Philip SS, Janardana R, Shenoy P, et al.

    Journal of scleroderma and related disorders 2024; (9(1)):29-37 doi:10.1177/23971983231215470.

    PMID: 38333526
  2. 2

    The serum levels of specific autoantibodies in systemic sclerosis predict a more severe skin involvement.

    Dengler H, Vonow-Eisenring M, Becker MO, et al.

    Journal of scleroderma and related disorders 2025; 23971983251357991 doi:10.1177/23971983251357991.

    PMID: 40746331
  3. 3

    Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort.

    Sáez-Comet L, Simeón-Aznar CP, Pérez-Conesa M, et al.

    The Journal of rheumatology 2015; (42(12)):2327-31 doi:10.3899/jrheum.150144.

    PMID: 26472418
  4. 4

    Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: A cross-sectional study from a single center of the Chinese Rheumatism Data Center.

    Li H, Zhang X, Yu L, et al.

    Frontiers in medicine 2022; (9()):1061738 doi:10.3389/fmed.2022.1061738.

    PMID: 36561716
  5. 5

    Correlation Between the Peak of Skin Thickness Progression Rate and Onset of Cardiopulmonary Involvement in Thai Systemic Sclerosis Patients.

    Rujirawinitchai P, Foocharoen C, Mahakkanukrauh A, et al.

    Journal of clinical medicine 2025; (14(7)) doi:10.3390/jcm14072281.

    PMID: 40217731
  6. 6

    Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.

    Lescoat A, Huang S, Carreira PE, et al.

    JAMA dermatology 2023; (159(8)):837-847 doi:10.1001/jamadermatol.2023.1729.

    PMID: 37378994
  7. 7

    A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways.

    Jimenez SA, Mendoza FA, Piera-Velazquez S

    Frontiers in immunology 2025; (16()):1551911 doi:10.3389/fimmu.2025.1551911.

    PMID: 40308583
  8. 8

    [High anti-topoisomerase-1 autoantibodies levels are associated with the extension of skin fibrosis and vascular progression in patients with systemic sclerosis].

    Dol C, Granel B, Resseguier N, et al.

    La Revue de medecine interne 2024; (45(3)):126-131 doi:10.1016/j.revmed.2023.11.006.

    PMID: 38355359
  9. 9

    Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort.

    Elhai M, Sritharan N, Boubaya M, et al.

    The Lancet. Rheumatology 2022; (4(11)):e785-e794 doi:10.1016/S2665-9913(22)00217-X.

    PMID: 38265945
  10. 10

    Characteristics of patients with systemic sclerosis living in Qatar.

    Alam F, Abdulaziz HM, Ul Haq I, et al.

    Qatar medical journal 2019; (2019(3)):16 doi:10.5339/qmj.2019.16.

    PMID: 31903322
  11. 11

    Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort.

    Zanatta E, Huscher D, Ortolan A, et al.

    Rheumatology (Oxford, England) 2022; (61(12)):4786-4796 doi:10.1093/rheumatology/keac188.

    PMID: 35348643
  12. 12

    Systemic sclerosis complicated by azathioprine-induced iatrogenic immunodeficiency-associated lymphoproliferative disorder: A case report.

    Okazaki R, Inui G, Funaki Y, et al.

    Modern rheumatology case reports 2025; (9(2)) doi:10.1093/mrcr/rxaf017.

    PMID: 40045598
  13. 13

    Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?

    Benyamine A, Bertin D, Heim X, et al.

    European journal of internal medicine 2017; (44()):e42-e44 doi:10.1016/j.ejim.2017.07.033.

    PMID: 28781194
  14. 14

    Frequency and determinants of use of immunosuppressants in the Australian Scleroderma Cohort Study.

    Fairley JL, Hansen D, Proudman S, et al.

    Journal of scleroderma and related disorders 2025; (10(3)):311-321 doi:10.1177/23971983251342690.

    PMID: 40416409
  15. 15

    Early diagnosis of systemic sclerosis, where do we stand today?

    Lepri G, Bellando Randone S, Matucci Cerinic M, Guiducci S

    Expert review of clinical immunology 2022; (18(1)):1-3 doi:10.1080/1744666X.2022.2015327.

    PMID: 35023438

This page is for educational purposes to help you understand systemic sclerosis subtypes and antibodies. Always discuss your specific lab results and health risks with your rheumatologist.

Get notified when new evidence is published on Systemic sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.